Headache in hemifacial spasm patients

被引:5
作者
Peeraully, T. [1 ]
Tan, S. -F. [1 ]
Fook-Chong, S. M. C. [2 ,3 ]
Prakash, K. M. [1 ,2 ]
Tan, E. -K. [1 ,2 ,4 ]
机构
[1] Singapore Gen Hosp, Dept Neurol, Singapore 169608, Singapore
[2] Duke NUS Grad Med Sch Singapore, Singapore, Singapore
[3] Singapore Gen Hosp, Dept Clin Res, Singapore 169608, Singapore
[4] Singapore Gen Hosp, Dept Neurol, Natl Neurosci Inst, Singapore 169608, Singapore
来源
ACTA NEUROLOGICA SCANDINAVICA | 2013年 / 127卷 / 05期
关键词
botulinum toxin; headache; hemifacial spasm; severity; quality of life; PLACEBO-CONTROLLED PHASE; DOUBLE-BLIND; ONABOTULINUMTOXINA; TRIAL;
D O I
10.1111/ane.12074
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives To assess prevalence of headaches in patients with hemifacial spasm. To determine whether hemifacial spasm provokes headaches and identifies predictive factors. To evaluate whether botulinum toxin given for hemifacial spasm improves headaches. Methods Seventy patients with hemifacial spasm were evaluated for headaches. The relationship of headaches with hemifacial spasm, impact on quality of life (HIT-6), and improvement in headaches from botulinum toxin was recorded. Data on duration, severity, and impact on quality of life (HFS-7) of hemifacial spasm were collected. Results Hemifacial spasm-related headache was significantly associated with increased hemifacial spasm severity (P<0.001) and HIT-6 (P=0.024). Greater hemifacial spasm severity was predictive of hemifacial spasm-related headache (P=0.006, OR 19.1, 95% CI 2.35155.64). Botulinum toxin (BTX) for hemifacial spasm improved hemifacial spasm-related headaches (P<0.001). Conclusions Hemifacial spasm can complicate headaches, particularly in patients with greater hemifacial spasm severity. Individually tailored regimens of botulinum toxin may be indicated in these patients.
引用
收藏
页码:e24 / e27
页数:4
相关论文
共 13 条
[1]  
Aurora SK, 2010, CEPHALALGIA, V30, P793, DOI 10.1177/0333102410364676
[2]   OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial [J].
Diener, H. C. ;
Dodick, D. W. ;
Aurora, S. K. ;
Turkel, C. C. ;
DeGryse, R. E. ;
Lipton, R. B. ;
Silberstein, S. D. ;
Brin, M. F. .
CEPHALALGIA, 2010, 30 (07) :804-814
[3]  
Husid Marc S., 2005, Headache, V45, P249, DOI 10.1111/j.1526-4610.2005.05053_3.x
[4]   Peripherally Induced Movement Disorders [J].
Jankovic, Joseph .
NEUROLOGIC CLINICS, 2009, 27 (03) :821-+
[5]   Combined hyperactive dysfunction syndrome of the cranial nerves: Trigeminal neuralgia, hemifacial spasm, and glossopharyngeal neuralgia: 11-year experience and review [J].
Kobata, H ;
Kondo, A ;
Iwasaki, K ;
Nishioka, T .
NEUROSURGERY, 1998, 43 (06) :1351-1361
[6]   A six-item short-form survey for measuring headache impact:: The HIT-6™ [J].
Kosinski, M ;
Bayliss, MS ;
Bjorner, JB ;
Ware, JE ;
Garber, WH ;
Batenhorst, A ;
Cady, R ;
Dahlöf, CGH ;
Dowson, A ;
Tepper, S .
QUALITY OF LIFE RESEARCH, 2003, 12 (08) :963-974
[7]   Migraine-tic syndrome: a case report of a new headache type [J].
Levin, M ;
Ward, TN ;
Larson, E .
CEPHALALGIA, 2004, 24 (01) :72-73
[8]   Botulinum toxin treatment of secondary headaches and cranial neuralgias: a review of evidence [J].
Linde, M. ;
Hagen, K. ;
Stovner, L. J. .
ACTA NEUROLOGICA SCANDINAVICA, 2011, 124 :50-55
[9]   A pilot study of botulinum toxin A for headache in cervical dystonia [J].
Ondo, WG ;
Gollomp, S ;
Galvez-Jimenez, N .
HEADACHE, 2005, 45 (08) :1073-1077
[10]   Validation of a short disease specific quality of life scale for hemifacial spasm: correlation with SF-36 [J].
Tan, EK ;
Fook-Chong, S ;
Lum, SY ;
Thumboo, J .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (12) :1707-1710